Xynomic Pharmaceuticals Holdings, Inc. Common Stock
XYN
XYN was delisted on the 16th of July, 2019.
0 hedge funds and large institutions have $0 invested in Xynomic Pharmaceuticals Holdings, Inc. Common Stock in 2019 Q3 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, reducing their positions, and 4 closing their positions.
100% less funds holding
Funds holding: 4 → 0 (-4)
100% less capital invested
Capital invested by funds: $73K → $0 (-$73K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 4
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
6CM
683 Capital Management
New York
|
-$34K |
| 2 |
YCM
Yakira Capital Management
Westport,
Connecticut
|
-$34K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$5K |
| 4 |
BI
Bulldog Investors
Saddle Brook,
New Jersey
|
-$34 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
6CM
1
683 Capital Management
New York
| – | -$34K | -10,000 | Closed |
|
|
BI
2
Bulldog Investors
Saddle Brook,
New Jersey
| – | -$34 | -10,000 | Closed |
|
|
YCM
3
Yakira Capital Management
Westport,
Connecticut
| – | -$34K | -10,000 | Closed |
|
|
4
UBS Group
Zurich,
Switzerland
| – | -$5K | -1,357 | Closed |
|
XYN Hedge Fund Activity: Q3 2019 in Review
0 of the 4,561 institutional investors tracked by Wall St. Rank reported a position in Xynomic Pharmaceuticals Holdings, Inc. Common Stock (XYN) for Q3 2019, worth a combined $0 — down 100% from $73K a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of XYN and 0 opened new positions — a net loss of 4 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was 683 Capital Management, exiting entirely with an estimated $34K sold.
- 0 institutional investors held Xynomic Pharmaceuticals Holdings, Inc. Common Stock (XYN) as of Q3 2019, down from 4 in Q2 2019.
- Funds reported $0 of Xynomic Pharmaceuticals Holdings, Inc. Common Stock stock for Q3 2019, down 100% quarter-over-quarter.
- 0 funds opened new Xynomic Pharmaceuticals Holdings, Inc. Common Stock positions in Q3 2019 and 4 closed out, a net change of -4 holders.
- The largest Xynomic Pharmaceuticals Holdings, Inc. Common Stock seller in Q3 2019 was 683 Capital Management, an estimated $34K sold.
Based on aggregated 13F filings for Q3 2019.